<DOC>
	<DOC>NCT00732602</DOC>
	<brief_summary>The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.</brief_summary>
	<brief_title>The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Caucasians over 18 years with type 1 diabetes (WHO criteria) Arginine test without rise in plasma Cpeptide Normal blood Hemoglobin Informed consent Liver disease Diabetic nephropathy Treatment with medications unpausable for 12 hours</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Glucagon</keyword>
	<keyword>Glucose-dependent Insulinotropic Polypeptide</keyword>
	<keyword>Glucagon-Like peptide 2</keyword>
</DOC>